Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report) were down 6.7% on Thursday . The company traded as low as $22.31 and last traded at $22.15. Approximately 45,239 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 291,052 shares. The stock had previously closed at $23.75.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.
View Our Latest Stock Analysis on Regencell Bioscience
Regencell Bioscience Price Performance
Regencell Bioscience (NASDAQ:RGC – Get Free Report) last posted its quarterly earnings results on Friday, May 8th. The company reported $0.00 EPS for the quarter.
Hedge Funds Weigh In On Regencell Bioscience
Several large investors have recently made changes to their positions in the company. Squarepoint Ops LLC acquired a new position in shares of Regencell Bioscience in the 2nd quarter valued at $1,701,000. BNP Paribas Financial Markets purchased a new stake in shares of Regencell Bioscience in the second quarter valued at approximately $768,000. XTX Topco Ltd purchased a new stake in shares of Regencell Bioscience in the third quarter valued at approximately $598,000. Vident Advisory LLC increased its position in shares of Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of Regencell Bioscience by 59,113.8% in the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after buying an additional 17,143 shares in the last quarter. 0.13% of the stock is currently owned by institutional investors and hedge funds.
About Regencell Bioscience
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Read More
- Five stocks we like better than Regencell Bioscience
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Regencell Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regencell Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
